PMID- 37770282
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240219
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 56
IP  - 3
DP  - 2024 Mar
TI  - Safety and effectiveness of direct-acting antiviral drugs in the treatment of 
      hepatitis C in patients with inflammatory bowel disease.
PG  - 468-476
LID - S1590-8658(23)00941-6 [pii]
LID - 10.1016/j.dld.2023.09.004 [doi]
AB  - BACKGROUND AND AIMS: Hepatitis C virus (HCV) management in Inflammatory Bowel 
      Disease (IBD) is uncertain. The ECCO guidelines 2021 recommended HCV treatment 
      but warn about the risk of IBD reactivation. We aimed to evaluate 1) the 
      effectiveness and safety of direct-acting antivirals (DAAs) in IBD; 2) the 
      interaction of DAAs with IBD drugs. METHODS: Multicentre study of IBD patients 
      and HCV treated with DAAs. Variables related to liver diseases and IBD, as well 
      as adverse events (AEs) and drug interactions, were recorded. McNemar's test was 
      used to assess differences in the proportion of active IBD during the study 
      period. RESULTS: We included 79 patients with IBD and HCV treated with DAAs from 
      25,998 IBD patients of the ENEIDA registry. Thirty-one (39.2 %) received 
      immunomodulators/biologics. There were no significant differences in the 
      percentage of active IBD at the beginning (n = 11, 13.9 %) or at the 12-week 
      follow-up after DAAs (n = 15, 19 %) (p = 0.424). Sustained viral response 
      occurred in 96.2 % (n = 76). A total of 8 (10.1 %) AEs occurred and these were 
      unrelated to activity, type of IBD, liver fibrosis, immunosuppressants/biologics, 
      and DAAs. CONCLUSIONS: We demonstrate a high efficacy and safety of DAAs in 
      patients with IBD and HCV irrespective of activity and treatment of IBD.
CI  - Copyright (c) 2023 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Martin-Cardona, A
AU  - Martin-Cardona A
AD  - Digestive Diseases Department, Hospital Universitari Mutua Terrassa, Terrassa, 
      Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y 
      Digestivas (CIBERehd), Madrid, Spain.
FAU - Horta, D
AU  - Horta D
AD  - Digestive Diseases Department, Hospital Universitari Mutua Terrassa, Terrassa, 
      Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y 
      Digestivas (CIBERehd), Madrid, Spain.
FAU - Florez-Diez, P
AU  - Florez-Diez P
AD  - Digestive Diseases Department, H.U. Central de Asturias, Oviedo, Spain.
FAU - Vela, M
AU  - Vela M
AD  - Digestive Diseases Department, H. Nuestra Sra. de la Candelaria, Santa Cruz de 
      Tenerife, Spain.
FAU - Mesonero, F
AU  - Mesonero F
AD  - Digestive Diseases Department, H. Ramon y Cajal, Madrid, Spain.
FAU - Ramos Belinchon, C
AU  - Ramos Belinchon C
AD  - Digestive Diseases Department, H. Gregorio Maranon, Madrid, Spain.
FAU - Garcia, M J
AU  - Garcia MJ
AD  - Gastroenterology and Hepatology Department, H. U. Marques de Valdecilla, IDIVAL, 
      Santander, Spain.
FAU - Masnou, H
AU  - Masnou H
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Madrid, Spain; Digestive Diseases Department, H.U. Germans Trias i 
      Pujol, Badalona, Spain.
FAU - de la Pena-Negro, L
AU  - de la Pena-Negro L
AD  - Digestive Diseases Department, H.U. Bellvitge, Hospitalet de Llobregat, Spain.
FAU - Suarez Ferrer, C
AU  - Suarez Ferrer C
AD  - Digestive Diseases Department, H. La Paz, Madrid, Spain.
FAU - Casanova, M J
AU  - Casanova MJ
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Madrid, Spain; Digestive Diseases Department, Hospital Universitario 
      de La Princesa-Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), 
      Madrid, Spain.
FAU - Duran, M Ortiz
AU  - Duran MO
AD  - Digestive Diseases Department, H.U. Infanta Cristina, Madrid, Spain.
FAU - Pena, E
AU  - Pena E
AD  - Digestive Diseases Department, Hospital Royo Villanova, Zaragoza, Spain.
FAU - Calvet, X
AU  - Calvet X
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Madrid, Spain; Digestive Diseases Department, Corporacio Sanitaria 
      Universitaria Parc Tauli, Sabadell, Spain.
FAU - Fernandez-Prada, S J
AU  - Fernandez-Prada SJ
AD  - Digestive Diseases Department, H. Rio Hortega, Valladolid, Spain.
FAU - Gonzalez-Munoza, C
AU  - Gonzalez-Munoza C
AD  - Digestive Diseases Department, H. de la Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Piqueras, M
AU  - Piqueras M
AD  - Digestive Diseases Department, Consorci Sanitari de Terrassa, Terrassa, Spain.
FAU - Rodriguez-Lago, I
AU  - Rodriguez-Lago I
AD  - Digestive Diseases Department, Hospital Universitario de Galdakao and Biocruces 
      Bizkaia Health Research Institute- Galdakao, Galdakao, Spain.
FAU - Sainz, E
AU  - Sainz E
AD  - Digestive Diseases Department, Althaia Xarxa Assistencial Universitaria de 
      Manresa, Manresa, Spain.
FAU - Bas-Cutrina, F
AU  - Bas-Cutrina F
AD  - Digestive Diseases Department, H. General de Granollers, Granollers, Spain.
FAU - Mancedino Marcos, N
AU  - Mancedino Marcos N
AD  - Digestive Diseases Department, Hospital Universitario Infanta Sofia, Madrid, 
      Spain.
FAU - Ojeda, A
AU  - Ojeda A
AD  - Digestive Diseases Department, H.G.U. Elche, Elche, Spain.
FAU - Orts, B
AU  - Orts B
AD  - Clinical Pharmacology Department, Hospital General Universitario de Alicante, 
      Alicante, Spain.
FAU - Sicilia, B
AU  - Sicilia B
AD  - Digestive Diseases Department, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Garcia, A Castano
AU  - Garcia AC
AD  - Digestive Diseases Department, H.U. Central de Asturias, Oviedo, Spain.
FAU - Domenech, E
AU  - Domenech E
AD  - Digestive Diseases Department, H.U. Germans Trias i Pujol, Badalona, Spain; 
      Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Madrid, Spain.
FAU - Esteve, M
AU  - Esteve M
AD  - Digestive Diseases Department, Hospital Universitari Mutua Terrassa, Terrassa, 
      Spain; Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y 
      Digestivas (CIBERehd), Madrid, Spain. Electronic address: mestevecomas@gmail.com.
CN  - ENEIDA registry of GETECCU
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230926
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Antiviral Agents)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - Antiviral Agents/adverse effects
MH  - Hepacivirus/genetics
MH  - *Hepatitis C, Chronic/complications/drug therapy
MH  - *Hepatitis C/drug therapy
MH  - *Inflammatory Bowel Diseases/complications/drug therapy
MH  - *Biological Products/therapeutic use
OTO - NOTNLM
OT  - Direct-acting antiviral drugs
OT  - Hepatitis C infection
OT  - Inflammatory bowel disease
COIS- Conflict of interest Dr. A. Martin-Cardona has received financial support for 
      conference attendance, educational activities, and research support from Abbvie, 
      Biogen, Faes Farma, Ferring, Jannsen, MSD, Pfizer, Takeda, Dr. Falk Pharma and 
      Tillotts. Dra. MJ Casanova has received research or education funding from 
      Pfizer, Takeda, Janssen, MSD, Ferring, Abbvie, Biogen, Faes Farma, Shire 
      Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi and Norgine. Dr. C. 
      Gonzalez-Munoza has received financial support for travel and educational 
      activities from Pfizer, Takeda, MSD, Norgine, Janssen, Tillots, and Kern Pharma. 
      Dra. M. Piqueras has served as a speaker or has received research or education 
      funding from Takeda, Abbvie and Janssen. Dr. I. Rodriguez-Lago has received 
      financial support for travelling and educational activities from or has served as 
      an advisory board member for Abbvie, Adacyte, Celltrion, Chiesi, Danone, Dr. Falk 
      Pharma, Ferring, Faes Farma, Janssen, Galapagos, MSD, Otsuka Pharmaceutical, 
      Pfizer, Roche, Takeda, and Tillotts Pharma. Dra. N. Mancenido Marcos has served 
      as a speaker and consultant for or has received financial support for educational 
      activities from Janssen, AbbVie, Pfizer, Takeda, Ferring, Faes Farma, Dr. Falk 
      Pharma and Tillotts Pharma. Dra. B. Sicilia has received research or education 
      funding or advisory fees from Abbvie, FAES, Chiesi, Dr. Falk, MSD, Tillots 
      Pharma, Khern Pharma, Janssen, Pfizer and Takeda. Dr. E. Domenech has served as a 
      speaker or has received research or education funding or advisory fees from 
      AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, Imidomics, 
      Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda and Tillots. Dra. M. 
      Esteve has received support for conference attendance and research support from 
      Abbvie, Biogen, Faes Farma, Ferring, Jannsen, MSD, Pfizer, Takeda, and Tillotts. 
      The remaining authors report no conflicts of interest related to this manuscript.
EDAT- 2023/09/29 00:42
MHDA- 2024/02/19 06:42
CRDT- 2023/09/28 21:53
PHST- 2023/04/25 00:00 [received]
PHST- 2023/08/22 00:00 [revised]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2024/02/19 06:42 [medline]
PHST- 2023/09/29 00:42 [pubmed]
PHST- 2023/09/28 21:53 [entrez]
AID - S1590-8658(23)00941-6 [pii]
AID - 10.1016/j.dld.2023.09.004 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2024 Mar;56(3):468-476. doi: 10.1016/j.dld.2023.09.004. Epub 2023 
      Sep 26.